TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02116322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA with Corkscrew technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expect 19 G Flex needle
Study: NCT00852397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 2.5 mg tablet BID for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 5.0 mg tablet BID for 24 weeks
Study: NCT02460861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RPVE
Description: Open Radical prostatovesiculectomy in Magdeburg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETRARP
Description: Robotassisted Radical prostatovesiculectomy in Gronau
Study: NCT00852397

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for 24 weeks
Study: NCT02460861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CE
Description: Open cystectomy in Magdeburg/Gronau

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsies of the prostatic fossa in gronau
Description: intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsies of the prostatic fossa in gronau
Description: intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
Study: NCT02906007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
Study: NCT03712046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Description: Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
Study: NCT03914469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention Group
Description: The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
Study: NCT04677894

Intervention type: DEVICE
Intervention: Laryngoscopy
Description: During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated

Intervention type: DEVICE
Intervention: Laryngoscopy
Description: During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
Study: NCT01438541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Window
Description: Dressing
Study: NCT02084862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous tracheostomy
Description: Ultrasound guided percutaneous tracheostomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy guided percutaneous tracheostomy
Description: Bronchoscopy guided percutaneous tracheostomy
Study: NCT04242277

Intervention type: DEVICE
Intervention: Investigational WF-OCT device
Description: Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
Study: NCT03859167

Intervention type: OTHER
Intervention: Stress Test
Description: Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
Study: NCT01692626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
Study: NCT04505657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib plus lidocaine
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Study: NCT01125189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peg-interferon alfa-2a
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
Study: NCT03490110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: State regulation skill training
Description: Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total \~4.5 hours per week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants receive clinical care as usual over a matched time period.
Study: NCT03835923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
Study: NCT01459133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation System
Description: Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Study: NCT01646372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Simulation Based ACLS Refresher Teaching
Description: 45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Simulation Based ACLS Refresher Teaching
Description: 45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Aid based ACLS Refresher training
Description: 45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
Study: NCT03825354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIC
Description: World Health Organization, WHO, Brief Intervention and Contact (BIC)
Study: NCT01799629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Study: NCT02641743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inslow
Description: carbohydrate adjusted liquid food using palatinose as the major carbohydrate (\>50%)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard balanced formula
Study: NCT03271801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: child health education
Description: 10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skills training
Description: 10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
Study: NCT02712320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMIS 50 mg
Description: Subcutaneous injection of 50 mg Leuprolide Mesylate
Study: NCT02462798

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain rye bread
Description: Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain sourdough rye bread
Description: Whole grain rye bread fermented with sourdough culture before baking
Study: NCT04604756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study: NCT02880670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Study: NCT03540888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep transverse Friction Massage
Description: The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic stretching intervention
Description: Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching intervention
Description: In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
Study: NCT00455403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
Study: NCT04391582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilapia skin
Description: After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
Study: NCT05958979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study: NCT04391582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silver sulfadiazine cream 1%
Description: After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
Study: NCT01142245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral esomeprazole
Description: • Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Esomeprazole
Description: Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours
Study: NCT00455403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
Study: NCT01771406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 8 weeks of Nebivolol treatment (5mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 8 weeks of Nebivolol treatment (5mg/day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: 8 weeks of CPAP treatment
Study: NCT05958979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study: NCT00110396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a FBS-free/HSA-free
Description: Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
Study: NCT00653627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Mycobacterium bovis Bacille Calmette-Guerin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Mycobacterium bovis Bacille Calmette-Guerin
Study: NCT05669404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt Restriction Group (SRG)
Description: Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Diet combined with salt restriction Group (DDG)
Description: Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet combined with salt restriction Group (MDG)
Description: Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
Study: NCT03248687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: The intervention will be method of follow up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: The intervention will be method of follow up.
Study: NCT01008566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT03973606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heath literacy assessment in Arab women in East Jerusalem
Description: A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
Study: NCT01131455

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Concentrated Plasma
Description: Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Concentrated Plasma
Description: Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
Study: NCT01332344

Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination
Description: Asthma subjects newly prescribed fluticasone propionate/salmeterol combination

Intervention type: DRUG
Intervention: Inhaled corticosteroids
Description: asthma subjects newly prescribed inhaled corticosteroids in clinical practice
Study: NCT03466450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Capsule
Description: During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Study: NCT03238651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.
Study: NCT00581750

Intervention type: OTHER
Intervention: Tissue specimen
Description: Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
Study: NCT03859427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.